Earlier this month, powerhouse Genzyme Corp. disclosed its launch of Phase III trials with the toxin binder tolevamer for patients with Clostridium difficile-associated diarrhea - a compound that derives from the same platform that yielded Renagel, the phosphate binder approved for end-stage renal disease that pulled in $364 million in revenue last year, up 29 percent over 2003. (BioWorld Financial Watch)